25-Year follow-up of HIV-positive patients with benign lymphoepithelial cysts of the parotid glands

A retrospective review

Waleed F. Mourad, Rebekah Young, Rafi Kabarriti, Dukagjin M. Blakaj, Rania A. Shourbaji, Jonathan Glanzman, Shyamal Patel, Nitin Ohri, Ravindra Yaparpalvi, Jonathan J. Beitler, Shalom Kalnicki, Madhur K. Garg

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim: To report long-term outcomes for HIV-positive patients who underwent radiation therapy (RT) for benign lymphoepithelial cysts (BLEC) of the parotid glands. Patients and Methods: In this single institution retrospective study of HIV-associated BLEC of the parotids, the medical records of 37 HIV-positive patients who were treated with RT between 1987-2012 were reviewed. Patients were stratified into two groups; group A consisted of 15 patients (40.5%) who received a total dose of ≤18Gy, with a median dose 10 Gy (range 8-18Gy), and group B consisted of 22 patients (59.5%) who received a total dose of 24 Gy. In addition to dosing information, additional patient data were collected, including demographics, HAART compliance, follow-up, and re-treatment status. Results: The median age at the time of treatment was 41 (range=7-70) years. With a median follow-up of 35 (range=12-75) months for the entire cohort, the complete response (CR) and partial response (PR) rates were 35% and 8%, respectively. All but one of 15 patients in Group A (lower total dose) eventually experienced local failure with the re-emergence of parotid hypertrophy. Among the patients in group B (higher total dose of 24 Gy), 55%, 13%, and 32% experienced CR, PR, and LF, respectively. Median times to failure in groups A and B were 7 and 20 months, respectively (p<0.0001). Similarly, logistic regression test revealed the higher dose to be associated with better response rate (i.e. CR or PR) (p<0.0001), which was also statistically significant (p=0.03) after adjusting for confounding variables (age, race, gender, HAART use, and fractionation). Conclusion: A total dose of 24 Gy continues to be recommended for durable cosmetic control of BLEC of the parotid glands that is associated with HIV-seropositivity.

Original languageEnglish (US)
Pages (from-to)4927-4932
Number of pages6
JournalAnticancer Research
Volume33
Issue number11
StatePublished - Nov 1 2013

Fingerprint

Parotid Gland
Cysts
HIV
Highly Active Antiretroviral Therapy
Radiotherapy
HIV Seropositivity
Confounding Factors (Epidemiology)
Cosmetics
Hypertrophy
Medical Records
Retrospective Studies
Logistic Models
Demography
Therapeutics

Keywords

  • Benign lymphoepitheilial cysts (BLEC)
  • Highly active antiretroviral therapy (HAART)
  • HIV positive
  • Parotid gland hyperplasia
  • Radiation therapy (RT)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mourad, W. F., Young, R., Kabarriti, R., Blakaj, D. M., Shourbaji, R. A., Glanzman, J., ... Garg, M. K. (2013). 25-Year follow-up of HIV-positive patients with benign lymphoepithelial cysts of the parotid glands: A retrospective review. Anticancer Research, 33(11), 4927-4932.

25-Year follow-up of HIV-positive patients with benign lymphoepithelial cysts of the parotid glands : A retrospective review. / Mourad, Waleed F.; Young, Rebekah; Kabarriti, Rafi; Blakaj, Dukagjin M.; Shourbaji, Rania A.; Glanzman, Jonathan; Patel, Shyamal; Ohri, Nitin; Yaparpalvi, Ravindra; Beitler, Jonathan J.; Kalnicki, Shalom; Garg, Madhur K.

In: Anticancer Research, Vol. 33, No. 11, 01.11.2013, p. 4927-4932.

Research output: Contribution to journalArticle

Mourad, WF, Young, R, Kabarriti, R, Blakaj, DM, Shourbaji, RA, Glanzman, J, Patel, S, Ohri, N, Yaparpalvi, R, Beitler, JJ, Kalnicki, S & Garg, MK 2013, '25-Year follow-up of HIV-positive patients with benign lymphoepithelial cysts of the parotid glands: A retrospective review', Anticancer Research, vol. 33, no. 11, pp. 4927-4932.
Mourad WF, Young R, Kabarriti R, Blakaj DM, Shourbaji RA, Glanzman J et al. 25-Year follow-up of HIV-positive patients with benign lymphoepithelial cysts of the parotid glands: A retrospective review. Anticancer Research. 2013 Nov 1;33(11):4927-4932.
Mourad, Waleed F. ; Young, Rebekah ; Kabarriti, Rafi ; Blakaj, Dukagjin M. ; Shourbaji, Rania A. ; Glanzman, Jonathan ; Patel, Shyamal ; Ohri, Nitin ; Yaparpalvi, Ravindra ; Beitler, Jonathan J. ; Kalnicki, Shalom ; Garg, Madhur K. / 25-Year follow-up of HIV-positive patients with benign lymphoepithelial cysts of the parotid glands : A retrospective review. In: Anticancer Research. 2013 ; Vol. 33, No. 11. pp. 4927-4932.
@article{5477aafc0ee4448090400c2044635079,
title = "25-Year follow-up of HIV-positive patients with benign lymphoepithelial cysts of the parotid glands: A retrospective review",
abstract = "Aim: To report long-term outcomes for HIV-positive patients who underwent radiation therapy (RT) for benign lymphoepithelial cysts (BLEC) of the parotid glands. Patients and Methods: In this single institution retrospective study of HIV-associated BLEC of the parotids, the medical records of 37 HIV-positive patients who were treated with RT between 1987-2012 were reviewed. Patients were stratified into two groups; group A consisted of 15 patients (40.5{\%}) who received a total dose of ≤18Gy, with a median dose 10 Gy (range 8-18Gy), and group B consisted of 22 patients (59.5{\%}) who received a total dose of 24 Gy. In addition to dosing information, additional patient data were collected, including demographics, HAART compliance, follow-up, and re-treatment status. Results: The median age at the time of treatment was 41 (range=7-70) years. With a median follow-up of 35 (range=12-75) months for the entire cohort, the complete response (CR) and partial response (PR) rates were 35{\%} and 8{\%}, respectively. All but one of 15 patients in Group A (lower total dose) eventually experienced local failure with the re-emergence of parotid hypertrophy. Among the patients in group B (higher total dose of 24 Gy), 55{\%}, 13{\%}, and 32{\%} experienced CR, PR, and LF, respectively. Median times to failure in groups A and B were 7 and 20 months, respectively (p<0.0001). Similarly, logistic regression test revealed the higher dose to be associated with better response rate (i.e. CR or PR) (p<0.0001), which was also statistically significant (p=0.03) after adjusting for confounding variables (age, race, gender, HAART use, and fractionation). Conclusion: A total dose of 24 Gy continues to be recommended for durable cosmetic control of BLEC of the parotid glands that is associated with HIV-seropositivity.",
keywords = "Benign lymphoepitheilial cysts (BLEC), Highly active antiretroviral therapy (HAART), HIV positive, Parotid gland hyperplasia, Radiation therapy (RT)",
author = "Mourad, {Waleed F.} and Rebekah Young and Rafi Kabarriti and Blakaj, {Dukagjin M.} and Shourbaji, {Rania A.} and Jonathan Glanzman and Shyamal Patel and Nitin Ohri and Ravindra Yaparpalvi and Beitler, {Jonathan J.} and Shalom Kalnicki and Garg, {Madhur K.}",
year = "2013",
month = "11",
day = "1",
language = "English (US)",
volume = "33",
pages = "4927--4932",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "11",

}

TY - JOUR

T1 - 25-Year follow-up of HIV-positive patients with benign lymphoepithelial cysts of the parotid glands

T2 - A retrospective review

AU - Mourad, Waleed F.

AU - Young, Rebekah

AU - Kabarriti, Rafi

AU - Blakaj, Dukagjin M.

AU - Shourbaji, Rania A.

AU - Glanzman, Jonathan

AU - Patel, Shyamal

AU - Ohri, Nitin

AU - Yaparpalvi, Ravindra

AU - Beitler, Jonathan J.

AU - Kalnicki, Shalom

AU - Garg, Madhur K.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Aim: To report long-term outcomes for HIV-positive patients who underwent radiation therapy (RT) for benign lymphoepithelial cysts (BLEC) of the parotid glands. Patients and Methods: In this single institution retrospective study of HIV-associated BLEC of the parotids, the medical records of 37 HIV-positive patients who were treated with RT between 1987-2012 were reviewed. Patients were stratified into two groups; group A consisted of 15 patients (40.5%) who received a total dose of ≤18Gy, with a median dose 10 Gy (range 8-18Gy), and group B consisted of 22 patients (59.5%) who received a total dose of 24 Gy. In addition to dosing information, additional patient data were collected, including demographics, HAART compliance, follow-up, and re-treatment status. Results: The median age at the time of treatment was 41 (range=7-70) years. With a median follow-up of 35 (range=12-75) months for the entire cohort, the complete response (CR) and partial response (PR) rates were 35% and 8%, respectively. All but one of 15 patients in Group A (lower total dose) eventually experienced local failure with the re-emergence of parotid hypertrophy. Among the patients in group B (higher total dose of 24 Gy), 55%, 13%, and 32% experienced CR, PR, and LF, respectively. Median times to failure in groups A and B were 7 and 20 months, respectively (p<0.0001). Similarly, logistic regression test revealed the higher dose to be associated with better response rate (i.e. CR or PR) (p<0.0001), which was also statistically significant (p=0.03) after adjusting for confounding variables (age, race, gender, HAART use, and fractionation). Conclusion: A total dose of 24 Gy continues to be recommended for durable cosmetic control of BLEC of the parotid glands that is associated with HIV-seropositivity.

AB - Aim: To report long-term outcomes for HIV-positive patients who underwent radiation therapy (RT) for benign lymphoepithelial cysts (BLEC) of the parotid glands. Patients and Methods: In this single institution retrospective study of HIV-associated BLEC of the parotids, the medical records of 37 HIV-positive patients who were treated with RT between 1987-2012 were reviewed. Patients were stratified into two groups; group A consisted of 15 patients (40.5%) who received a total dose of ≤18Gy, with a median dose 10 Gy (range 8-18Gy), and group B consisted of 22 patients (59.5%) who received a total dose of 24 Gy. In addition to dosing information, additional patient data were collected, including demographics, HAART compliance, follow-up, and re-treatment status. Results: The median age at the time of treatment was 41 (range=7-70) years. With a median follow-up of 35 (range=12-75) months for the entire cohort, the complete response (CR) and partial response (PR) rates were 35% and 8%, respectively. All but one of 15 patients in Group A (lower total dose) eventually experienced local failure with the re-emergence of parotid hypertrophy. Among the patients in group B (higher total dose of 24 Gy), 55%, 13%, and 32% experienced CR, PR, and LF, respectively. Median times to failure in groups A and B were 7 and 20 months, respectively (p<0.0001). Similarly, logistic regression test revealed the higher dose to be associated with better response rate (i.e. CR or PR) (p<0.0001), which was also statistically significant (p=0.03) after adjusting for confounding variables (age, race, gender, HAART use, and fractionation). Conclusion: A total dose of 24 Gy continues to be recommended for durable cosmetic control of BLEC of the parotid glands that is associated with HIV-seropositivity.

KW - Benign lymphoepitheilial cysts (BLEC)

KW - Highly active antiretroviral therapy (HAART)

KW - HIV positive

KW - Parotid gland hyperplasia

KW - Radiation therapy (RT)

UR - http://www.scopus.com/inward/record.url?scp=84891351664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891351664&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 4927

EP - 4932

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 11

ER -